Ko Yamamoto, Hirotoshi Watanabe, Takeshi Morimoto, Yuki Obayashi, Masahiro Natsuaki, Kyohei Yamaji, Takenori Domei, Manabu Ogita, Masanobu Ohya, Shojiro Tatsushima, Hirohiko Suzuki, Tomohisa Tada, Mitsuru Ishii, Akira Nikaido, Naoki Watanabe, Shinya Fujii, Hiroyoshi Mori, Tenjin Nishikura, Nobuhiro Suematsu, Fujio Hayashi, Kota Komiyama, Tatsuya Shigematsu, Tsuyoshi Isawa, Satoru Suwa, Kenji Ando, Takeshi Kimura
BACKGROUND: Diabetes was reported to be associated with an impaired response to clopidogrel. OBJECTIVES: The aim of this study was to evaluate the safety and efficacy of clopidogrel monotherapy after very short dual antiplatelet therapy (DAPT) in patients with diabetes undergoing percutaneous coronary intervention (PCI). METHODS: A subgroup analysis was conducted on the basis of diabetes in the STOPDAPT-2 (Short and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-2) Total Cohort (N = 5,997) (STOPDAPT-2, n = 3,009; STOPDAPT-2 ACS [Short and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-2 for the Patients With ACS], n = 2,988), which randomly compared 1-month DAPT followed by clopidogrel monotherapy with 12-month DAPT with aspirin and clopidogrel after cobalt-chromium everolimus-eluting stent implantation...
January 9, 2023: JACC. Cardiovascular Interventions